We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC
Read MoreHide Full Article
Clovis Oncology, Inc. announced that the FDA has granted Breakthrough Therapy designation for its cancer drug, Rubraca (rucaparib). The designation was granted for treating BRCA1/2 mutated metastatic castration resistant prostate cancer (mCRPC), based on initial data from phase II TRITON2 study. Currently, the study is evaluating the drug in mCRPC patients with BRCA mutations and ATM mutations.
Later this month, data will be presented at the European Society for Medical Oncology (“ESMO”) Congress to be held in Germany.
We note that the Breakthrough Therapy designation from the FDA should accelerate the development and review of drugs that are intended to treat serious or life-threatening diseases.
Following the latest announcement, shares of the company jumped 7.7% on Oct 2. However, Clovis’ stock has lost 53.8% so far this year compared with the industry’s 1.8% decline.
Rubraca, a PARP-inhibitor, is already approved for treating ovarian cancer in second-line setting in the United States, where it competes with AstraZeneca’s (AZN - Free Report) Lynparza and TESARO’s Zejula. Approval for second-line maintenance treatment was granted by the FDA in April.
A regulatory application for the similar maintenance treatment for ovarian cancer is under review in Europe, where it is approved for platinum-sensitive and relapsing ovarian cancer patients with BRCA-mutation in third- or later-line setting.
Notably, Clovis is focused on developing the drug in different types of ovarian cancer along with other types of cancer.
While a phase III study – TRITON 3 – is also evaluating Rubraca in mCRPC, a phase II ATLAS study is evaluating the drug in bladder cancer.
This apart, Clovis has a collaboration agreement with Merck (MRK - Free Report) and Bristol-Myers to develop Rubraca in combination with their PD-1/ PDL1 inhibitors for treating several cancer indications.
In the first half of 2018, Rubraca’s sales have almost doubled compared with the figure registered a year ago. Successful development of the drug in the ongoing studies will boost its prospect further.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
Image: Bigstock
Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC
Clovis Oncology, Inc. announced that the FDA has granted Breakthrough Therapy designation for its cancer drug, Rubraca (rucaparib). The designation was granted for treating BRCA1/2 mutated metastatic castration resistant prostate cancer (mCRPC), based on initial data from phase II TRITON2 study. Currently, the study is evaluating the drug in mCRPC patients with BRCA mutations and ATM mutations.
Later this month, data will be presented at the European Society for Medical Oncology (“ESMO”) Congress to be held in Germany.
We note that the Breakthrough Therapy designation from the FDA should accelerate the development and review of drugs that are intended to treat serious or life-threatening diseases.
Following the latest announcement, shares of the company jumped 7.7% on Oct 2. However, Clovis’ stock has lost 53.8% so far this year compared with the industry’s 1.8% decline.
Rubraca, a PARP-inhibitor, is already approved for treating ovarian cancer in second-line setting in the United States, where it competes with AstraZeneca’s (AZN - Free Report) Lynparza and TESARO’s Zejula. Approval for second-line maintenance treatment was granted by the FDA in April.
A regulatory application for the similar maintenance treatment for ovarian cancer is under review in Europe, where it is approved for platinum-sensitive and relapsing ovarian cancer patients with BRCA-mutation in third- or later-line setting.
Notably, Clovis is focused on developing the drug in different types of ovarian cancer along with other types of cancer.
While a phase III study – TRITON 3 – is also evaluating Rubraca in mCRPC, a phase II ATLAS study is evaluating the drug in bladder cancer.
This apart, Clovis has a collaboration agreement with Merck (MRK - Free Report) and Bristol-Myers to develop Rubraca in combination with their PD-1/ PDL1 inhibitors for treating several cancer indications.
In the first half of 2018, Rubraca’s sales have almost doubled compared with the figure registered a year ago. Successful development of the drug in the ongoing studies will boost its prospect further.
Clovis Oncology, Inc. Price
Clovis Oncology, Inc. Price | Clovis Oncology, Inc. Quote
Zacks Rank
Clovis currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>